KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Work In Process (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Work In Process for 15 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 2.49% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 million through Dec 2025, up 2.49% year-over-year, with the annual reading at $30.9 million for FY2025, 2.49% up from the prior year.
  • Work In Process for Q4 2025 was $30.9 million at Halozyme Therapeutics, down from $34.8 million in the prior quarter.
  • The five-year high for Work In Process was $56.2 million in Q3 2022, with the low at $6.3 million in Q1 2022.
  • Average Work In Process over 5 years is $31.9 million, with a median of $32.5 million recorded in 2023.
  • The sharpest move saw Work In Process plummeted 67.43% in 2022, then skyrocketed 332.75% in 2023.
  • Over 5 years, Work In Process stood at $17.5 million in 2021, then skyrocketed by 152.72% to $44.1 million in 2022, then dropped by 22.85% to $34.0 million in 2023, then dropped by 11.33% to $30.2 million in 2024, then increased by 2.49% to $30.9 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $30.9 million, $34.8 million, and $30.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.